Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 88 peer-reviewed journal articles Updated
Hematology

Understanding Myeloproliferative Neoplasms (MPNs): Validation & Orientation

At a Glance

Myeloproliferative neoplasms (MPNs) are rare blood cancers caused by genetic mutations that make the bone marrow overproduce blood cells. The three main types—ET, PV, and PMF—are highly manageable, and many patients live long, full lives with proper monitoring and care.

Receiving a diagnosis of a myeloproliferative neoplasm (MPN) often brings a mix of confusion and fear. While the word neoplasm is a medical term for an abnormal growth of tissue (a tumor or cancer), MPNs are different from the “solid tumor” cancers most people think of, such as breast or lung cancer [1][2].

MPNs are blood cancers that start in the bone marrow, the factory where your body makes blood cells [1]. In a healthy person, the marrow produces exactly the right number of cells. In someone with an MPN, a genetic “glitch” or mutation causes the marrow to overproduce one or more types of blood cells [3][4]. For many people, these conditions are managed more like a chronic illness—such as diabetes or heart disease—than an aggressive malignancy [5].

The Three Main Types of MPNs

MPNs are classified based on which type of blood cell is being overproduced. There are three “classical” types:

  1. Essential Thrombocythemia (ET): The body makes too many platelets, the cells that help your blood clot [6].
  2. Polycythemia Vera (PV): The body makes too many red blood cells, which can make the blood thicker [6].
  3. Primary Myelofibrosis (PMF): This involves an overproduction of cells that leads to fibrosis (scarring) in the bone marrow, making it harder for the marrow to produce healthy blood [5][6].

Understanding the Rarity

If your local doctor seems less familiar with these conditions, it is because they are statistically rare. For every 100,000 people, roughly 1.5 to 1.6 are diagnosed with ET or PV each year [6][7]. PMF is even rarer, occurring in about 0.3 to 0.44 per 100,000 people [6][8]. Because these are “orphan diseases,” many patients find it helpful to consult with an MPN specialist—a hematologist who focuses specifically on these rare blood disorders.

Stabilizing Facts for Your Journey

While the diagnosis is serious, there are several reasons to feel grounded as you begin your care:

  • Chronic and Manageable: Many patients with ET or PV have a life expectancy that is near normal, provided they receive appropriate monitoring and treatment to prevent complications like blood clots [9][8].
  • Targeted Science: Researchers have identified specific “driver mutations”—the most common being JAK2, CALR, and MPL—which act like broken switches keeping the cell factory “on” [1][4]. Understanding your specific mutation helps your doctor tailor your care [10].
  • Personalized Pace: Every patient’s journey is unique. Your disease may remain stable for decades, or it may require more active management. Current guidelines emphasize risk stratification, which means your treatment is based on your specific risk factors, not a “one size fits all” approach [11][12].
  • Focus on Quality of Life: Modern care is not just about “fixing blood counts.” Doctors now use tools to track your symptom burden—like fatigue, night sweats, or itching—to ensure your treatment is actually helping you feel better in your daily life [13][14].

You are not just a set of lab results. While your bone marrow is working overtime, your medical team’s job is to help you navigate this diagnosis with clarity and a plan that protects your long-term health [14][11].

Guide Index

To continue learning about your diagnosis, explore the following sections:

01

The Biology of MPNs: Subtypes and Genetic Drivers

Understand the biology of myeloproliferative neoplasms (MPNs). Learn about PV, ET, and PMF subtypes, and what JAK2, CALR, and MPL driver mutations mean.

02

Navigating Your Diagnosis and Pathology Report

Learn how to read your MPN pathology report. Understand terms like bone marrow biopsy, reticulin fibrosis, VAF, and get a checklist for your diagnosis.

03

Standard of Care and Treatment Strategies for MPNs

Learn about standard treatments for MPNs like PV, ET, and myelofibrosis. Understand phlebotomy targets, hydroxyurea, JAK inhibitors, and when to switch.

04

Prognosis, Risk Scores, and Long-Term Outlook

Learn how to understand your MPN prognosis and risk scores. Find out what IPSET, DIPSS, and high-molecular-risk mutations mean for your long-term outlook.

05

Living with an MPN: Symptoms, Surveillance, and Survivorship

Learn how to manage myeloproliferative neoplasm (MPN) symptoms, track your quality of life with the MPN-10, and understand your surveillance schedule.

Common questions in this guide

Is a myeloproliferative neoplasm considered cancer?
Yes, an MPN is a type of blood cancer that starts in the bone marrow. However, unlike aggressive solid tumors, many MPNs are managed more like long-term chronic illnesses such as diabetes or heart disease.
What are the different types of MPNs?
The three classical types are Essential Thrombocythemia (ET), Polycythemia Vera (PV), and Primary Myelofibrosis (PMF). They are classified based on whether your bone marrow is overproducing platelets, red blood cells, or scar tissue.
What causes an MPN?
MPNs are caused by acquired genetic mutations in the bone marrow cells. The most common driver mutations are JAK2, CALR, and MPL, which act like a broken switch that keeps the blood cell factory turned on.
What is the life expectancy for someone with an MPN?
Many patients with ET or PV have a life expectancy that is near normal as long as they receive appropriate monitoring and treatment. Care primarily focuses on symptom management and preventing complications like blood clots.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.What is my specific MPN subtype (ET, PV, or PMF), and was this confirmed via a bone marrow biopsy?
  2. 2.Which driver mutation do I have (JAK2, CALR, or MPL), and how does that influence my outlook?
  3. 3.Based on my age and medical history, am I considered 'low risk' or 'high risk' for blood clots?
  4. 4.What are the specific goals of my treatment right now—managing symptoms, preventing clots, or something else?
  5. 5.How many patients with MPNs do you currently treat in your practice?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (14)
  1. 1

    Haploidentical donor hematopoietic cell transplantation for myelodysplastic/myeloproliferative overlap neoplasms: results from a North American collaboration.

    Jain T, Tsai HL, Elmariah H, et al.

    Haematologica 2023; (108(12)):3321-3332 doi:10.3324/haematol.2023.283426.

    PMID: 37408464
  2. 2

    Genetic basis and molecular pathophysiology of classical myeloproliferative neoplasms.

    Vainchenker W, Kralovics R

    Blood 2017; (129(6)):667-679 doi:10.1182/blood-2016-10-695940.

    PMID: 28028029
  3. 3

    Primary myelofibrosis: 2017 update on diagnosis, risk-stratification, and management.

    Tefferi A

    American journal of hematology 2016; (91(12)):1262-1271 doi:10.1002/ajh.24592.

    PMID: 27870387
  4. 4

    Clinical and Laboratory Features of JAK2 V617F, CALR, and MPL Mutations in Malaysian Patients with Classical Myeloproliferative Neoplasm (MPN).

    Zulkeflee RH, Zulkafli Z, Johan MF, et al.

    International journal of environmental research and public health 2021; (18(14)) doi:10.3390/ijerph18147582.

    PMID: 34300032
  5. 5

    Combination of myeloproliferative neoplasm driver gene activation with mutations of splice factor or epigenetic modifier genes increases risk of rapid blastic progression.

    Bartels S, Vogtmann J, Schipper E, et al.

    European journal of haematology 2021; (106(4)):520-528 doi:10.1111/ejh.13579.

    PMID: 33460496
  6. 6

    Changes in the incidence and overall survival of patients with myeloproliferative neoplasms between 2002 and 2016 in the United States.

    Verstovsek S, Yu J, Scherber RM, et al.

    Leukemia & lymphoma 2022; (63(3)):694-702 doi:10.1080/10428194.2021.1992756.

    PMID: 34689695
  7. 7

    Epidemiology of the Philadelphia Chromosome-Negative Classical Myeloproliferative Neoplasms.

    Shallis RM, Zeidan AM, Wang R, Podoltsev NA

    Hematology/oncology clinics of North America 2021; (35(2)):177-189 doi:10.1016/j.hoc.2020.11.005.

    PMID: 33641862
  8. 8

    Epidemiology of the classical myeloproliferative neoplasms: The four corners of an expansive and complex map.

    Shallis RM, Wang R, Davidoff A, et al.

    Blood reviews 2020; (42()):100706 doi:10.1016/j.blre.2020.100706.

    PMID: 32517877
  9. 9

    Classic myeloproliferative neoplasms in Singapore: A population-based study on incidence, trends, and survival from 1968 to 2017.

    Htun HL, Lian W, Wong J, et al.

    Cancer epidemiology 2022; (79()):102175 doi:10.1016/j.canep.2022.102175.

    PMID: 35569302
  10. 10

    Update from the latest WHO classification of MPNs: a user's manual.

    Passamonti F, Maffioli M

    Hematology. American Society of Hematology. Education Program 2016; (2016(1)):534-542 doi:10.1182/asheducation-2016.1.534.

    PMID: 27913526
  11. 11

    Myeloproliferative Neoplasms, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology.

    Mesa R, Jamieson C, Bhatia R, et al.

    Journal of the National Comprehensive Cancer Network : JNCCN 2016; (14(12)):1572-1611 doi:10.6004/jnccn.2016.0169.

    PMID: 27956542
  12. 12

    Impact of Molecular Biology in Diagnosis, Prognosis, and Therapeutic Management of BCR::ABL1-Negative Myeloproliferative Neoplasm.

    Abbou N, Piazzola P, Gabert J, et al.

    Cells 2022; (12(1)) doi:10.3390/cells12010105.

    PMID: 36611899
  13. 13

    Approach to MPN Symptom Assessment.

    Geyer H, Mesa RA

    Current hematologic malignancy reports 2017; (12(5)):381-388 doi:10.1007/s11899-017-0399-5.

    PMID: 28942516
  14. 14

    Daily living and rehabilitation needs in patients and caregivers affected by myeloproliferative neoplasms (MPN): A qualitative study.

    Rossau HK, Kjerholt M, Brochmann N, et al.

    Journal of clinical nursing 2022; (31(7-8)):909-921 doi:10.1111/jocn.15944.

    PMID: 34231273

This page provides an educational overview of myeloproliferative neoplasms (MPNs). It is for informational purposes only and does not replace professional medical advice from a qualified hematologist or oncologist.

Get notified when new evidence is published on Myeloproliferative neoplasm.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.